Rigel Pharmaceuticals (RIGL) Liabilities and Shareholders Equity (2010 - 2026)

Rigel Pharmaceuticals' Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $504.6 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 186.75% year-over-year to $504.6 million; the TTM figure through Mar 2026 stood at $1.5 billion (up 141.45% YoY), while the FY2025 annual figure was $513.6 million, up 213.21% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $504.6 million, down from $513.6 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $513.6 million in Q4 2025, with the low at $115.3 million in Q3 2023.
• The 5-year median for Liabilities and Shareholders Equity is $134.3 million (2022), against an average of $188.4 million.
• The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity plunged 38.02% in 2022, then surged 213.21% in 2025.
• Rigel Pharmaceuticals' Liabilities and Shareholders Equity stood at $134.3 million in 2022, then retreated by 12.7% to $117.2 million in 2023, then surged by 39.88% to $164.0 million in 2024, then soared by 213.21% to $513.6 million in 2025, then retreated by 1.75% to $504.6 million in 2026.
• Business Quant data shows RIGL's Liabilities and Shareholders Equity at $504.6 million in Q1 2026, $513.6 million in Q4 2025, and $242.5 million in Q3 2025.